Study ID: CTSU C80702

Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer


The purpose of this study is to evaluate the effects of different chemotherapy treatments. Participants in this study have cancer of the colon, which has been surgically removed, but has spread to lymph nodes (Resected Stage III Colon Cancer). One of the common combinations of chemotherapy drugs used to treat your type of cancer includes 5-fluorouracil (5-FU), leucovorin and oxaliplatin, and is also called ┬┐FOLFOX┬┐. This study will evaluate the effects of an oral drug called celecoxib when given in combination with FOLFOX chemotherapy. An additional purpose of this study is to determine if giving celecoxib (by mouth) and chemotherapy decreases the risk of colon cancer recurrence.

Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Principal Investigator:
Preston Steen, MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Phase III


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list